Get the Stockscreener App
0.7501
38.01%
-0.4599
Pre-market:
.72
-0.0301
-4.01%
Plus Therapeutics Inc Stock (PSTV) Latest News
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph
Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan
Plus Therapeutics Regains Nasdaq Compliance - Nasdaq
Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia
Plus Therapeutics regains Nasdaq compliance - Investing.com India
SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow
Plus Therapeutics regains Nasdaq compliance status - Investing.com India
Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement - GlobeNewswire
Plus Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - Nasdaq
Plus Therapeutics Secures Future on Nasdaq After Meeting Equity Requirements - StockTitan
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy - MSN
Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday - Insider Monkey
Plus Therapeutics Announces Peer-Reviewed Publication in - GlobeNewswire
Plus Therapeutics Continues Rally On FridayHere's Why - Benzinga
Plus Therapeutics' Brain Cancer Therapy Shows Promise in Early-Stage Study; Shares Rise - Marketscreener.com
Pre-Hour Momentum Drives Plus Therapeutics (PSTV) Stock Higher On FDA Designation - Stocks Telegraph
FDA ODD given to Plus Therapeutics’ injectable radiotherapy - Yahoo Finance
Breakthrough Brain Cancer Treatment Doubles Patient Survival: Phase 1 Results Revealed - StockTitan
RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial - Nature.com
Plus Therapeutics’ $15 Million Private Placement - Global Legal Chronicle
Pharma Stock Plus Therapeutics, Inc. (Nasdaq: $PSTV) Makes NASDAQ Top Gainer List on FDA News - Investorideas.com newswire
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Gets FDA Orphan Drug Designation for Rhenium Obisbemeda in Lung Cancer; Shares Surge - Marketscreener.com
Plus Therapeutics stock rises on FDA Orphan tag (PSTV:NASDAQ) - Seeking Alpha
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment By Investing.com - Investing.com South Africa
FDA grants orphan drug status to Plus Therapeutics’ cancer treatment - Investing.com
Plus Therapeutics secures $5.7M to support leptomeningeal metastases program - MSN
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation For Rhenium (186Re) Obisbemeda - Marketscreener.com
Plus Therapeutics granted Orphan Drug Designation for Rhenium Obisbemeda - TipRanks
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation - GlobeNewswire
Can This Rare FDA Designation Transform Plus Therapeutics' Cancer Treatment Future? - StockTitan
Plus Therapeutics Announces New Employment Inducement Grants - The Manila Times
Plus Therapeutics Awards 30,000 Stock Options to Newly Appointed CDOWhat's the Vesting Timeline? - StockTitan
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - GlobeNewswire
Plus Therapeutics Expects $15 Million in Gross Proceeds From Private Placement of Units; Shares Fall - Marketscreener.com
Plus Therapeutics tumbles on $15M private placement - MSN
Plus Therapeutics sees $15M in gross proceeds from private placement - TipRanks
Plus Therapeutics, Inc. Announces $15 Million Private Placement to Advance CNS Cancer Therapies - Nasdaq
Can Plus Therapeutics' $15M Financing Solve Its Nasdaq Delisting Challenge? - StockTitan
Leptomeningeal Metastases Market Anticipated to Expand - openPR
Understanding the Risks of Investing in Plus Therapeutics Inc (PSTV) - Knox Daily
Glioma Treatment Market Size Report 2034 | AnHeart Therapeutics - openPR
Plus Therapeutics (PSTV) Projected to Post Quarterly Earnings on Tuesday - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Plus Therapeutics, Inc. Advances Lead Drug Rhenium Obisbemeda for Patients with Leptomeningeal Metastases - Marketscreener.com
Plus Therapeutics sets dose for CNS cancer treatment trial By Investing.com - Investing.com Canada
Plus Therapeutics sets dose for CNS cancer treatment trial - Investing.com India
Plus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Establishes RP2D for Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases - Nasdaq
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with ... - The Bakersfield Californian
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases - GlobeNewswire
Cancer Breakthrough? Plus Therapeutics' Drug Shows Complete Response in Difficult-to-Treat Brain Cancer Patient - StockTitan
Stromal Vascular Fraction Market to Reach USD 280.1 million by 2034, Poised for Significant Expansion | Exclusive Report by TMR - PharmiWeb.com
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary - GlobeNewswire
Plus Therapeutics Appoints Russell Bradley as the President - citybiz
Plus Therapeutics appoints Russell Bradley as president, CNSide - TipRanks
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - The Manila Times
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):